Table 4.

Synergy of gentamicin and SEQ-914 against MRSA-295 biofilms in CAMHB

Treatment groupConcn (μg/ml)aLog10 no. of CFU/biofilm (mean ± SD)bLog reduction
Pretreatmentc8.24 ± 0.29
Untreated control9.34 ± 0.07
GEN29.03 ± 0.07−0.79
47.99 ± 0.080.25
86.11 ± 0.212.14
163.87 ± 0.644.37
SEQ-914168.57 ± 0.06−0.33
325.86 ± 0.532.39
GEN–SEQ-9140.5; 8d5.79 ± 1.012.45
1; 47.50 ± 0.170.75
1; 84.44 ± 0.693.81
2; 27.15 ± 0.481.10
2; 46.70 ± 0.281.55
2; 83.59 ± 0.424.66
  • a Biofilm assay concentration.

  • b A minimum of two independent experiments were performed, with three wells per experiment. Data are reported as averages (n = 6 as a minimum) for these experiments.

  • c This is the biofilm at 5 h prior to treatment.

  • d GEN and SEQ-914 concentrations, respectively.